No Data
No Data
Madrigal Pharmaceuticals Price Target Raised to $460.00/Share From $422.00 by B. Riley Securities
Madrigal Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
Madrigal Pharmaceuticals Analyst Ratings
UBS Adjusts Madrigal Pharmaceuticals Price Target to $458 From $441, Maintains Buy Rating
Analysts Conflicted on These Healthcare Names: Madrigal Pharmaceuticals (MDGL) and AptarGroup (ATR)
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Sell Rating, Raises Target Price to $248